Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib

Darapladib, a lipoprotein-associated phospholipase A2 (Lp-PLA(2)) inhibitor, failed to demonstrate efficacy for the primary endpoints in two large phase III cardiovascular outcomes trials, one in stable coronary heart disease patients (STABILITY) and one in acute coronary syndrome (SOLID-TIMI 52). N...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeo, Astrid, Li, Li, Warren, Liling, Aponte, Jennifer, Fraser, Dana, King, Karen, Johansson, Kelley, Barnes, Allison, MacPhee, Colin, Davies, Richard, Chissoe, Stephanie, Tarka, Elizabeth, O’Donoghue, Michelle L., White, Harvey D., Wallentin, Lars, Waterworth, Dawn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533343/
https://www.ncbi.nlm.nih.gov/pubmed/28753643
http://dx.doi.org/10.1371/journal.pone.0182115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533343/
https://www.ncbi.nlm.nih.gov/pubmed/28753643
http://dx.doi.org/10.1371/journal.pone.0182115

Ejemplares similares